Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 11, 2002, Pages 4914-4923

  Christopher Gallagher, J ^a   Rapuri, Prema B ^a   Haynatzki, Gleb ^a   Detter, Jeff R ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CALCITRIOL; CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE REMODELING; CALCIUM ABSORPTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ESTROGEN THERAPY; FEMALE; FEMUR NECK; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE;

ABSORPTION; AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; CALCIFEDIOL; CALCITRIOL; CALCIUM; COLLAGEN; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FEMUR; HUMANS; OSTEOCALCIN; PARATHYROID HORMONE; PEPTIDES; PLACEBOS; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 0036845372     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020727     Document Type: Article

References (26)

1. Lindsay R, Hart DM, MacLean A, Clark AC, Kraszewski A, Garwood J 1978 Bone response to termination of estrogen treatment. Lancet 1:1325-1327
2. Horsman A, Nordin BE, Crilly RG 1979 Effect on bone of withdrawal of estrogen therapy. Lancet 2:33
3. Fogelman I, Bessent RG, Cohen HN, Hart DM, Lindsay R 1980 Skeletal uptake of diphophonate. Method for prediction of postmenopausal osteoporosis. Lancet 2:667-670
4. Tremollieres FA, Pouilles JM, Ribot C 2001 Withdrawal of hormone replacement therapy is associated with significant vertebral bone loss in postmenopausal women. Osteop Int 12:385-390
5. Christiansen C, Christensen MS, Transbol I 1981 Bone mass in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy. Lancet 1:459-461
6. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E 2002 Bone mass response to discontinuation of long-term hormone replacement therapy. Arch Intern Med 162:665-672
7. Eiken P, Nielsen SP, Kolthoff N 1997 Effects on bone mass after eight years of hormonal replacement therapy. Br J Obstet Gynaecol 107:702-707
8. Stock JL, Bell NH, Chesnut III CH, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wie L, Santora II AC 1997 Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291-297
9. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE 2000 Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 72:745-750
10. 3). Endocrinol Jpn 32:305-315
11. Gallagher JC, Fowler SE, Detter JR, Sherman SS 2001 Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 86:3618-3628
12. Haddad JG, Chyu KJ 1971 Competitive protein-binding radioassay for 25-hydroxycholecalciferol. J Clin Endocrinol Metab 33:992-995
13. 2D. In: Norman AW, Schaefer K, Grigoleit HG, Herratt DV, eds. Vitamin D, Molecular, Cellular and Clinical Endocrinology. Berlin, New York: de Gruyter; 720-726
14. Bullamore JR, Wilkinson R, Gallagher JC, Nordin BE, Marshall DH 1970 Effect of age on calcium absorption. Lancet 2:535-537
15. Davis JW, Ross PD, Johnson NE, Wasnich RD 1995 Estrogen and calcium supplement use among Japanese American women: Effect upon bone loss when used singly and in combination. Bone 17:369-373
16. Saarto T, Vehmanen L, Elomaa I, Valimaki M, Makela P, Blomqvist C 2001 The effect of clodronate and antiestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 84:1047-1051
17. Bush TL, Wells BH, James MK, Barrett-Connor, Marcus R, Greendale G, Hunsberger S, McGowan J 1996 Effects of hormone therapy on bone mineral density. Results from the Postmenopausal Estrogen/Progestin Interventioins (PEPI) Trial. JAMA 276:1389-1396
18. Schneider DL, Barrett-Connor Morton DJ 1997 Timing of postmenopausal estrogen for optimal bone mineral density. JAMA 277:543-547
19. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR 1980 Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 303:1195-1198
20. Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM 1981 Menopausal estrogen therapy and hip fractures. Ann Intern Med 95:28-31
21. Cauley JA, Seeely DG, Ensrud K, Ettinger B, Black D, Cummings SR 1995 Estrogen replacement therapy and fractures in older women. Ann Intern Med 122:9-16
22. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ 1993 The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329:1141-1146
23. Randell KM, Honkanen RJ, Kroger H, Saarikoshi S 2002 Does hormone-replacement therapy prevent fractures m early postmenopausal women. J Bone Miner Res 17:528-533
24. Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz 1987 Hip fracture and the use of estrogens in postmenopausal women. The Framingham study. N Engl J Med 317:1169-1174
25. Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S 1998 Hormone replacement therapy and risk of hip fracture: Population based case-control study. Br Med J 316:1858-1863
26. Thomsen K, Riis BJ, Johansen JS, Christiansen C, Rodbor P 1987 Bone remover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy. Gynecol Endocrinol 1:169-175